cAMPfield Therapeutics

cAMPfield Therapeutics is developing a potentially best-in-class oral PDE4B-selective inhibitor for inflammatory bowel disease.

Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2026
C AM Pfield Tx Hover Image